Abstract
The present invention relates to pharmaceutical combinations of at least one thiopurine and/or at least a pharmaceutically acceptable salt and/or at least one prodrug thereof and riboflavin to treat patients suffering from inflammatory bowel disease (IBD) or other inflammatory conditions. This invention also relates to additive and/or combinations of at least one thiopurine and riboflavin. This invention is also related to a method for the treatment or prophylaxis of IBD or other inflammatory conditions, which method comprises administering a therapeutically effective amount of thiopurine and riboflavin.
Original language | English |
---|---|
Patent number | WO2020161088 |
Priority date | 04/02/2019 |
Filing date | 04/02/2020 |
Publication status | Published - 13-Aug-2020 |